《大行》交银国际:AI技术驱动医药板块新机遇 荐信达生物(01801.HK)翰森制药(03692.HK)中生制药(01177.HK)等

阿斯达克财经
Feb 17, 2025

交银国际近日发表研究报告指,AI技术正驱动医药板块发展,带来新机遇,建议投资者关注AI相关的创新技术以及其所推动的估值修复机会,指出近日医渡科技(02158.HK) 、恒瑞医药(600276.SH) 、信达生物(01801.HK) 等多间医药公司宣布已接入或将接入DeepSeek,预期AI+医疗加速落地将协助企业提升医药研发效率、优化药物设计,为CRO和创新药企带来利好作用。憧憬中央将出台财政及...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10